Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
A
T-024
A Bayesian Approach to Item Response Theory Modeling for Exposure-Response Relationships in Stan
Favorite
M-135
A Bayesian disease progression model for Major Depressive Disorder
Favorite
T-131
A Bayesian Model-based CTS Tool to Optimize Clinical Trial Design in Duchenne Muscular Dystrophy
Favorite
T-078
A Bayesian Semi-Mechanistic Dose-Finding Design for Phase I Drug Combination Trials in Oncology
Favorite
M-061
A clinical trial simulator tool for a randomized delayed start trial in Parkinson’s disease
Favorite
T-084
A COMBINED EX VIVO AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC APPROACH TO INCORPORATE DRUG-DRUG INTERACTIONS FOR DOSING DURING CONTINUOUS RENAL REPLACEMENT THERAPY
Favorite
T-088
A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD
Favorite
T-116
A DeepNLME-based Tumor Growth Dynamics and Overall Survival Model for Non Small Cell Lung Cancer
Favorite
T-071
A Framework for Evaluating Predictive Models Using Synthetic Image Covariates and Longitudinal Data
Favorite
T-117
A High-Dose Methotrexate Dashboard: Integrating MTXPK.org into the Electronic Health Record to Facilitate Model-Informed Care for Pediatric Patients with Malignant Conditions
Favorite
T-013
A hybrid semi-mechanistic and machine learning framework to predict Cytokine Release Syndrome following T-cell engaging immunotherapies
Favorite
M-002
A Longitudinal Model-based Meta-Analysis (MBMA) of Body Weight in Obesity Trials
Favorite
M-126
A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages
Favorite
T-079
A mechanistic QSP model of CRS allows for quantitative assessment of dose priming of CD3 bispecific antibody (BsAb) therapeutics.
Favorite
M-089
A minimal PBPK model to study the effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody PK
Favorite
M-134
A Minimal Physiology-based Pharmacokinetics Model of Blood-Brain Barrier Transport for Monoclonal Antibodies Targeting the Transferrin Receptor
Favorite
M-030
A Minimal QSP Model for Treg Responses of IL-2 Mutein MK-6194 – A Conceptual Model for Autoimmune Disease
Favorite
T-046
A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289
Favorite
W-138
A model-based framework for assessing schedule dependence of therapeutic window for three-drug combinations
Favorite
T-001
A Model-based Pharmacokinetic Simulation Tool to Aid Dose Selection of Antisense Oligonucleotides Administered Intrathecally in Pediatrics
Favorite
T-103
A model-based simulation workflow enables automated and accurate generation of clinical pharmacology summary statistics, a workflow and case-study.
Favorite
M-106
A Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies
Favorite
T-056
A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building
Favorite
T-011
A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab
Favorite
T-018
A Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model to Describe Pathophysiology of Alzheimer’s Disease and Inform Drug Development
Favorite
M-090
A Novel Approach to Capturing the Dynamics of Nontarget and New Tumors in Mechanistic Models of Progression-Free Survival
Favorite
T-066
A Novel Concentration-Based Time-Imputation Algorithm for Large Cohort Studies Missing Time-After-Dose Data for Stored Samples
Favorite
T-036
A Novel Empirical Drug Induced Autoinduction Model to Characterize the Population Pharmacokinetics of Repotrectinib with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Favorite
T-070
A novel model for Platelets Dynamics: a pragmatic systems approach to characterize thrombocytopenia across multiple compounds and drug classes
Favorite
T-005
A novel PBPK/PD model of preclinical data projects the human pharmacologically active dose of a Biologic that modulates immunosuppressive immune cells in the tumor microenvironment
Favorite
M-039
A PBPK-QSP model for regulation of thyroid hormones in Allan-Herndon Dudley Syndrome
Favorite
M-057
A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model
Favorite
T-062
A Pharmacologically-informed Neural Ordinary Differential Equation Framework to Predict Preclinical Pharmacokinetics
Favorite
T-080
A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity
Favorite
W-009
A Physiological-Based Pharmacokinetic (PBPK) Model embedded with Pulmonary Compartmental Absorption and Transit (PCAT™️) Module to Predict Intranasal Ketamine Pharmacokinetics in Pediatric Population
Favorite
M-137
A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
Favorite
T-129
A prototype mechanistic systems pharmacology model of Type 2 interventions in eosinophilic esophagitis
Favorite
T-101
A QSP model of atopic dermatitis to accelerate the clinical translation of novel combination therapies
Favorite
M-025
A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease
Favorite
T-122
A Quantitative Systems Pharmacology Approach to Understand the Variability of Patient Response to T-cell Bi-specifics in Hematological Malignancies
Favorite
M-110
A quantitative systems pharmacology model for diabetes-induced glomerular fibrosis
Favorite
T-010
A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates
Favorite
M-100
A Quantitative Systems Pharmacology Model of LNP-mRNA Uptake Through LDLR Binding
Favorite
T-015
A quantitative systems pharmacology model to explore resistance mechanisms and combination strategies in ALK+ NSCLC targeted therapies
Favorite
T-067
A quantitative systems pharmacology-physiologically based pharmacokinetic model-guided antibiotics regimen design for the treatment of sepsis and septic shock patients
Favorite
T-050
A review of OSP suite PBBM capabilities: looking ahead
Favorite
M-073
A Scalable Cloud-Based QSP Modeling System for Virtual Patient Generation
Favorite
M-017
A Semi-mechanistic Pharmacokinetic-Pharmacodynamic/Toxicodynamic Model to Guide Dose Optimization of Combination Therapies Targeting DNA Damage Response Pathways
Favorite
M-064
A semi-mechanistic pharmacometrics model to quantitatively characterize delta-9-tetrahydrocannabinol (THC) and its metabolites’ disposition among oral cannabis users
Favorite
T-026
A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
Favorite
M-072
A shared pool modeling approach to describe antibody-mediated cell-cell interactions
Favorite
M-011
A Survey of Model Informed Approaches in Neuroscience Drug Development
Favorite
M-028
A systematic approach for imputing missing dose information in population pharmacokinetic analysis datasets
Favorite
M-014
A systematic efficacy analysis of multidrug therapies for tuberculosis using a multi-scale agent-based model
Favorite
M-136
A time-to-event model for Bronchopulmonary dysplasia based on real-world data
Favorite
T-033
A translational one pore and two pore whole body physiologically based pharmacokinetic model for ASOs, and siRNA-based therapeutics
Favorite
M-068
A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor
Favorite
M-056
A Translational Quantitative Systems Pharmacology (QSP) Modeling Framework to Predict Interleukin-15 (IL-15) Cytokine Levels in Multiple Myeloma Patients after Anti-BCMA CAR-NK Cell Therapy
Favorite
T-044
A translational quantitative systems pharmacology modeling framework for FcRn antagonist therapy for myasthenia gravis
Favorite
M-032
A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
Favorite
M-008
A within-host dynamic model of Bordetella pertussis to support vaccine development
Favorite
M-052
Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin
Favorite
T-099
Acoramidis (ALXN2060) Population Pharmacokinetic Modeling and the Importance of Exploring Categorization of Covariate Values
Favorite
M-130
Across-species meta-analysis of methylprednisolone reversible metabolism and pharmacokinetics utilizing allometric and scaling model approaches
Favorite
W-033
Adaptation of a Published Kidney Disease QSP Model to Represent Autosomal-Dominant Polycystic Kidney Disease and Evaluate Treatment Options
Favorite
T-104
Adaptation of the Glucose, Glucagon, Gastric-Inhibitory Peptide, Glucagon-like Peptide-1, and Insulin (4GI) Model for Simulation of Acute Meal Challenges with Infused Antagonists
Favorite
M-099
Advancing Drug Development in Relapsed and Refractory Multiple Myeloma (RRMM): Assessing the Safety and Efficacy Landscape Utilizing Model-Based Meta-Analysis
Favorite
M-079
Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach
Favorite
T-043
Advancing Drug Development through Enhanced Exposure-Response Analysis: The R-Shiny App ERpmx
Favorite
T-063
Advancing Modeling of Hematologic Safety using a Semi-mechanistic Multivariate PK/PD Approach: Application to the ATR Inhibitor Tuvusertib in Early Phase Oncology Development
Favorite
M-109
Advancing Quantitative Systems Pharmacology Model for Inflammatory Bowel Disease for Clinical Efficacy Predictions in Ulcerative Colitis
Favorite
T-060
AI-Driven Innovative Platform in Quantitative Pharmacology: Literature Insights and Automated Model Construction
Favorite
M-006
An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine
Favorite
T-068
An integrated model of catabolic clearance mechanisms driving exposure-response confounding for immunotherapies in cancer: interactions between mAb drugs, Fc receptors, and endogenous serum proteins
Favorite
W-077
An Introduction to Campsis: The R-Based Open-Source PK/PD Simulation Suite
Favorite
T-029
An R-based workflow for clinical trial simulation tool with application in type 1 diabetes studies
Favorite
T-048
App-based in vitro pharmacokinetic driver identification and in silico clinical trial assessment of pharmacokinetic driver models
Favorite
T-017
Application of an advanced gut PBPK model to characterize intestinal transport and P-glycoprotein-mediated drug-drug interaction: a case study with Digoxin and Clarithromycin
Favorite
W-006
Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Favorite
T-112
Application of Machine Learning Methods to Predict Risk of Adverse Events in Clinical Trials
Favorite
T-081
Application of Model Informed Drug Development (MIDD) to BT8009, a Bicycle Toxin Conjugate (BTC®), in Patients with Advanced Urothelial Cancer
Favorite
T-128
Application of PKPD Principles to Drive the Discovery and Development of Novel BCR-ABL Tyrosine Kinase Inhibitors
Favorite
T-083
Application of quantitative systems pharmacology modeling in reverse translation
Favorite
T-115
Approaches for Developing a Robust Virtual Twin Workflow in Quantitative Systems Pharmacology Models
Favorite
M-116
Approaches of Incorporating Prior Information in Pediatric PopPK Model Development with Limited Data
Favorite
M-083
Assessing Parameter Impacts on ADC Efficacy and Toxicity: Capabilities and Limitations of Sensitivity Analysis in an Innovative Full Physiologically Based Pharmacokinetic Pharmacodynamic Framework
Favorite
T-120
Assessing Sirolimus and Antiretroviral Interactions in People with HIV on Chronic ART: A Population Pharmacokinetic Approach in Non-Transplant Recipients
Favorite
T-069
Assessment of Disease Similarity among Different Racial and/or Ethnic Groups in Oncology: ABC Framework
Favorite
M-026
Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen
Favorite
M-097
Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation
Favorite
M-129
Automating Translational Physiologically Based Pharmacokinetic Modeling with R and Simcyp: An Innovative Approach
Favorite
